FDA Approves Tepmetko (tepotinib) for People with Metastatic Non-Small Cell Lung Cancer with MET-Exon 14 Mutation
Tepmetko (tepotinib) initially received accelerated approval in 2021 based on initial results from the VISION study, which evaluated the use of Tepmetko (tepotinib) in people with metastatic NSCLC with a MET-Exon 14 skipping mutation.The new traditional (not accelerated) approval is based on the inclusion
Tepmetko (tepotinib) initially received accelerated approval in 2021 based on initial results from the VISION study, which evaluated the use of Tepmetko (tepotinib) in people with metastatic NSCLC with a MET-Exon 14 skipping mutation.The new traditional (not accelerated) approval is based on the inclusion
